❓Tech Q&A | Niraparib HCl has #antitumor activity and shows some cytotoxicity
🔸At appropriate concentrations, it typically does not add extra toxicity to normal cells
🔸Can be used directly as a #PARP inhibitor after dissolution, no desalting required

#PARPInhibitor #CancerResearch #CellBiology

Repurposed Drugs Target Junk DNA in Tough Blood Cancers

King's College London researchers found repurposing PARP inhibitor drugs can exploit junk DNA activity in myelodysplastic syndrome and chronic lymphocytic leukemia, leading to DNA damage. getnews.me/repurposed-drugs-target-... #bloodcancer #parpinhibitor

Watch an excerpt from yesterday's #ICARE #Genetics Case Conference during which Elizabeth Swisher, MD from the University of Washington discusses Myelodysplastic Syndrome (#MDS) and Acute Myeloid #Leukemia (#AML) following #PARPinhibitor therapy ⤸
youtu.be/t4PthACSQ00

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.

#Onco404 #Cancer #Kanser #MedSky #OncSky #BRCAness #HRD #BRCA1 #BRCA2 #PlatinumChemotherapy #PARPInhibitor #TargetedTherapy #Vocabulary

Tumor-Agnostic Trial Finds PARP Inhibitor and Anti-PD-L1 Combo Beneficial Across Cancer Types Tumors that harbor mutations or deficiencies in DNA repair pathways may respond to the combination of a PARP inhibitor and immune checkpoint inhibitor, with tumors positive for BRCA1/2 mutations espec...

Tumour-agnostic trial shows promise: Combining #olaparib + #pembrolizumab proves effective across multiple cancer types with #HRR or #HRD mutations in the KEYLYNK-007 study. A big step in oncology. #CancerResearch #PARPinhibitor #Immunotherapy #TCSC

www.oncologynewscentral.com/oncology/tum...

💡 Importance
This case challenges the paradigm of PARPi use beyond breast/ovarian cancers and highlights precision oncology’s power in complex, resistant settings.

#Onco404 #Oncology #Cancer #PrecisionOncology #LungCancer #PARPInhibitor #CancerResearch #CaseReport

1️⃣ 73% tumor shrinkage post-olaparib + intrathecal chemo.
2️⃣ 18+ months progression-free survival (longest reported for PARPi in NSCLC-LM!).
3️⃣ Dramatic immune microenvironment shifts: CD8+/CD4+ T-cell influx, reduced suppressive cells.

#Onco404 #Oncology #Cancer #LungCancer #PARPInhibitor

Pfizer's Talzenna therapy accepted for use within NHS Scotland - PharmaTimes Scottish Medicines Consortium approves new option for mCRPC patients

#prostatecancer #Pfizer #Talzenna #talazoparib #Talzennatherapy #NHSScotland #ScottishMedicinesConsortium #SMCapprovel #mCRPCpatients #metastaticcastrationresistantprostatecancer #mCRPC #polyADPribosepolymeraseinhibitor #PARPinhibitor #metastaticprostatecancer
pharmatimes.com/news/pfizers...

NICE recommends olaparib for BRCA-mutated breast cancer treatment - PharmaTimes Groundbreaking approval provides new hope for patients in England and Wales

#precisionmedicine #PARPinhibitor #breastcancer #NICErecommended #olaparib #Lynparza #AstraZeneca #AstraZenecaUK #AstraZenecaOncology #genetictesting #OlympiADclinicaltrail #OlympiADphase3trial #BRCAmutations #TestingforBRCAmutations #NationalGenomicTestDirectory
pharmatimes.com/news/nice-re...

Really excited and grateful to receive this funding from @theaacr.bsky.social, which will allow Carmen and I to continue working on the molecular basis and consequences of heterogeneous #PARPinhibitor distribution in #ovariancancer ...first paper on this hopefully coming soon - watch this space!

🟣 November is #PancreaticCancer awareness month 🟣

Germline mutations in #PDAC include BRCA1, BRCA2, PALB2, CDK2A, ATM, & TP53. J’s oncologist ordered germline testing soon after diagnosis, & he had a gBRCA1 defect, targetable by #PARPinhibitor #olaparib. A welcome chemo break, & info for family!